NIKKEI 225
26,393.04 -411.56 (-1.54%) HANG SENG
21,859.79 -137.10 (-0.62%) CRUDE OIL
106.10 -3.68 (-3.35%) GOLD FUTURES
1,808.60 -8.90 (-0.49%) DOW
30,922.19 -107.12 (-0.35%) BTC-GBP
15,702.65 -845.70 (-5.11%)
MorphoSys AG (MOR.DE)
| Previous close | 19.23 |
| Open | 19.13 |
| Bid | 18.72 x 1500 |
| Ask | 18.75 x 8800 |
| Day's range | 18.20 - 19.14 |
| 52-week range | 16.45 - 67.46 |
| Volume | |
| Avg. volume | 163,132 |
| Market cap | 640.997M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.54 |
| Earnings date | 14 Mar 2022 - 18 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.86 |
- EQS Group
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys AG / Key word(s): AgreementMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 14.06.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, South San Francisco, United States, June 14, 2022MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 Human Immunology Biosciences (HIBio) is a biotechnology company focused
- Zacks
MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer
MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.
- EQS Group
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: MorphoSys AG / Key word(s): Agreement/MiscellaneousPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 13.06.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNew York, New York, U.S.; Boston, Massachusetts, U.S.; and Wilmington, Delaware, U.S., June 13, 2022Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboratio
